Provider Education Webinar Series

This series of webinars is geared towards medical providers who are interested in learning more about Tourette Syndrome treatment and management strategies. We invite physicians, nurses, nurse practitioners, and psychologists, regardless of Tourette Syndrome experience, to attend these webinars. All webinars will be accredited for CMEs; more information will be provided soon.

Identification and Management of ADHD and Impulse Control in Tourette Syndrome

Tuesday, March 9, 2021  3–4 pm EST

Attention Deficit Disorder, either the inattentive, hyperactive, or combined type is fairly common in patients with Tourette syndrome. Furthermore, impulse control disorders are common as well. Frequently, the functional impact of these conditions outweighs the impact of tics in the lives of these patients. This webinar will define both disorders and explore best ways to manage them in children and adults with Tourette Syndrome.

  1. To define ways ADHD can present and impact patients with Tourette syndrome
  2. To define ways impulse control can present and impact the lives of patients with Tourette syndrome
  3. To delineate the different treatments, whether behavioral, lifestyle or pharmacological, to manage both conditions.
Kompoliti Headshot 350

Speaker: Dr. Katie Kompoliti

Dr. Katie Kompoliti

Professor, Department of Neurological Sciences

Education Director, Section of Movement Disorders Department of Neurological Sciences

Rush University Medical Center

Aikaterini Kompoliti, MD, was born in Greece and completed her early education there, including medical school. After graduating from the University of Patras Medical School, Greece, she pursued her interest in neuroscience by completing a residency in neurology at Northwestern University, Chicago, followed by a fellowship in movement disorders at Rush University Medical Center, Chicago. After the completion of her fellowship, she became a faculty member in movement disorders in the Department of Neurological Sciences at Rush University Medical Center where she is currently professor of neurology.  She is the author and co-author of numerous publications. Her clinical interests as a principal investigator in research have focused on several therapeutic areas including studies to evaluate the safety and efficacy of new compounds to treat Parkinson’s disease, Tourette’s syndrome, functional movement disorders and dystonia. Furthermore, she is the educational director of the section of movement disorders and the director of the movement disorders fellowship at Rush University Medical Center.  Dr. Kompoliti is the director of a Center of Excellence on Tourette syndrome and Tic Disorders at Rush University Medical Center.

Refractory Tourette Syndrome

Thursday, April 8 TIME TBD

Achieving an effective treatment strategy for Tourette syndrome (TS) can be challenging in some cases, especially when associated co-morbidities or psychosocial factors influence disease manifestations. Since there is no current consensus on the definition of “refractory” TS, a framework of understanding “refractoriness” will be presented, including considerations related to proper diagnosis, symptom assessment, therapy dosing, adherence or side effects, and impact of co-occurring conditions and environmental influences. This case-based presentation will explore courses of action for clinicians to consider when symptom treatments in TS do not respond sufficiently to usual approaches.

  1. List factors that can contribute to poor response to treatment interventions in TS
  2. Assess relevant symptom severity relating to tics and co-morbidities
  3. Describe potential modifications to the treatment strategy when symptoms in TS do not respond sufficiently to usual approaches
Jimenez Shahed Joohi.691920.Neurology 350

Speaker: Dr. Joohi Jimenez-Shahed

Dr. Joohi Jimenez-Shahed

Associate Professor of Neurology, Movement Disorders and Neurosurgery

Ichan School of Medicine, Mount Sinai

Dr. Jimenez-Shahed is an Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai.  After completing her undergraduate degree at Washington University in St. Louis, Dr. Jimenez-Shahed received her medical degree from Baylor College of Medicine (BCM) and Neurology residency training at Duke University Medical Center. She then completed a fellowship in Movement Disorders at the Parkinson’s Disease Center and Movement Disorders Clinical (PDCMDC) at BCM. Her research interests lie in investigating the intraoperative neurophysiology of patients undergoing deep brain stimulation (DBS) for movement disorders.

Dr. Jimenez-Shahed serves as Chair of the Functional Neurosurgical Working Group of the Parkinson Study Group, and is the lead investigator for RAD-PD: a national quality improvement registry for patients undergoing DBS surgery for Parkinson’s disease. She is also an investigator with the Huntington Study Group, Dystonia Coalition and TSA International Database of DBS Studies in Tourette syndrome. She currently serves on the Science Advisory Board of the Davis Phinney Foundation and the Medical Advisory Board of the Tourette Association of America and has chaired the Medical Advisory Board for the Houston Area Parkinson Society. She has served as Principal Investigator for industry-sponsored and investigator-initiated clinical trials and has authored several papers and book chapters.

She is the recipient of the Roy H. Cullen Quality of Life Award (Houston Area Parkinson Society), the Rising Star Clinician Award (BCM), the Fulbright & Jaworski L.L.P. Faculty Excellence Award in Teaching and Evaluation (BCM) and the Healthcare Heroes Award for Outstanding Health Care Practitioner (Houston Business Journal). She was recognized as a Woman of Excellence at BCM and is a 2018 graduate of the inaugural Women Leading in Neurology program of the American Academy of Neurology.

Advances in the Treatment of Tics

Thursday, May 13, 2021  3 – 4pm EST

Motor and phonic tics associated with Tourette syndrome (TS) can range in severity from barely perceptible to disabling and most patients have a variety of behavioral co-morbidities, particularly, attention deficit disorder and obsessive-compulsive disorder. Therefore, therapy must be tailored to the individual needs of the patients. In addition to behavioral therapy, oral medications such as alpha agonists, dopamine depletors, anti-psychotics, and topiramate are used to control the involuntary movements and noises. Botulinum toxin injections are particularly effective in patients with troublesome focal motor and phonic tics, including coprolalia. Deep brain stimulation may be considered for patients with “malignant” TS, that is, refractory to medical therapy. When appropriate therapy is selected and implemented, most patients with TS can achieve their full potential and lead essentially normal life.

  1. To become familiar with the current therapeutic approach in patients with tics and Tourette syndrome.
  2. To understand the rationale for and basic pharmacology of novel drugs used in the treatment of Tourette syndrome.
  3. To learn about emerging medical and surgical treatments of tics.
Jankovic Picture Headshot B 10 20 350

Speaker: Dr. Joseph Jankovic

Dr. Joseph Jankovic

Professor of Neurology

Distinguished Chair in Movement Disorders Director, Parkinson’s Disease Center and Movement Disorders Clinic Director

Center of Excellence for Parkinson’s Foundation and Tourette Association of America

Baylor College of Medicine

Dr. Jankovic is a Professor of Neurology, Distinguished Chair in Movement Disorders, and Founder and Director of the Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC), Department of Neurology, Baylor College of Medicine, Houston, Texas. After completing his Neurology training at Columbia University, New York City, he joined the faculty of Baylor College of Medicine in 1977. Since that time he has led clinical team that focuses on the most compassionate and expert care and research on etiology, pathophysiology, and experimental therapeutics of Parkinson’s disease and related neurodegenerative and movement disorders such as tremors, dystonia, Tourette syndrome, Huntington disease, restless legs syndrome, tardive dyskinesia, and paroxysmal dyskinesias. Under the direction of Dr. Jankovic the PDCMDC has been recognized as “Center of Excellence” by the Parkinson’s Foundation, the Huntington Disease Society of America, the Tourette Association of America, and the Wilson Disease Association.

Past president of the International Parkinson and Movement Disorder Society and of the International Neurotoxin Association, Dr. Jankovic is the recipient of many awards including the American Academy of Neurology (AAN) Movement Disorders Research Award, First National Parkinson Foundation Distinguished Service Award, Huntington’s Disease Society of America Guthrie Family Humanitarian Award, Tourette Syndrome Association Lifetime Achievement Award, Dystonia Medical Research Foundation Distinguished Service Award, Benign Essential Blepharospasm Research Foundation Award, and Lifetime Achievement Award from the International Neurotoxin Association, Dr. Jankovic has been recognized as an Honorary Member of the American Neurological Association, Australian Association of Neurologists, French Neurological Society, and the International Parkinson’s Disease and Movement Disorders Society.


Dr. Jankovic has published over 1,200 original articles and over 55 books, is included among “Highly Cited Researchers”, and has been ranked #1 expert in the world in movement disorders and in botulinum toxins (


He has served as the principal investigator in hundreds of clinical trials and his pioneering research on drugs for parkinsonian disorders and hyperkinetic movement disorders has led to their approval by the Food and Drug Administration. Certified by the American Board of Psychiatry and Neurology, Dr. Jankovic is a fellow of the AAN and current or past member of many scientific and medical advisory boards and has served on the executive scientific advisory boards of the Michael J. Fox Foundation for Parkinson’s Research and the National Parkinson Foundation. Dr. Jankovic has mentored numerous fellows and other trainees many of whom have become leaders in the field of neurology and movement disorders. For further information visit

Transitioning to Adult Care: Time is Ticcing Away

Tuesday, July 13, 2021 from 3 – 4pm EST

In this webinar, we will discuss the process of transitioning from Pediatric to Adult care for patients with Tourette Syndrome, Chronic Tic Disorders, and co-occurring conditions. There are a number of dramatic contrasts between Pediatric and Adult medicine that often complicate transition process. For example, the dynamics of an adult medical visit are completely different than in a Pediatric medical visit. Also, coordination of care between medical providers is often more complicated and is more patient driven. Participants of this webinar will be presented with strategies to manage these and other challenges inherent to the transition process.

  1. At the end of this webinar, participants will be able to identify the hurdles that can impede successful transition to adult care and how to overcome them.
  2. At the end of this webinar, participants will be able to identify the significant contrasts between a Pediatric and Adult medical visit and use strategies to manage these contrasting models of care.
  3. At the end of this webinar, participants will be able to discuss how to advocate for themselves to facilitate effective care coordination between multiple medical providers.
FADCoffmanKeith18800x800 350

Speaker: Dr. Keith Coffman

Dr. Keith Coffman

Director, Tourette Syndrome Center of Excellence

Director, Movement Disorders Clinic

Children’s Mercy Hospital Kansas City

Keith Coffman, M.D., is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. His clinical specialties include tics and Tourette Syndrome; movement disorders; developmental delay; neurodegenerative disorders and neurogenetic disorders. Dr. Coffman attended medical school at Pennsylvania State University College of Medicine and completed his Pediatrics and Neurodevelopmental Disabilities residencies at Children’s Hospital of Pittsburgh of UPMC. This was followed by a research fellowship in Systems Neuroscience at the University of Pittsburgh. His research focus is on the neuroanatomy of the cerebellar vermis and its role in motor control and higher cognitive function.